APRILE, GIUSEPPE
 Distribuzione geografica
Continente #
NA - Nord America 381
EU - Europa 332
AS - Asia 107
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 825
Nazione #
US - Stati Uniti d'America 379
RU - Federazione Russa 167
IT - Italia 51
IE - Irlanda 38
SE - Svezia 28
HK - Hong Kong 27
PL - Polonia 26
CN - Cina 25
SG - Singapore 24
JO - Giordania 20
CH - Svizzera 8
IN - India 8
FI - Finlandia 4
GB - Regno Unito 4
CA - Canada 2
DE - Germania 2
FR - Francia 2
SS - ???statistics.table.value.countryCode.SS??? 2
VN - Vietnam 2
BR - Brasile 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
NL - Olanda 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 825
Città #
Santa Clara 107
Dublin 38
Chandler 36
Fairfield 31
Warsaw 26
Hong Kong 22
Singapore 22
Ashburn 18
Lawrence 14
Cambridge 12
Altamura 11
Houston 9
Moscow 9
Shanghai 9
Wilmington 9
Bern 8
Florence 8
Seattle 8
Woodbridge 8
Boston 7
Princeton 7
Ann Arbor 6
Mumbai 6
New York 6
Boardman 5
Buffalo 5
Rome 5
Beijing 4
Helsinki 4
Modena 4
San Diego 4
Yubileyny 4
Kent 3
London 3
Bologna 2
Dong Ket 2
Falls Church 2
Hillsboro 2
Juba 2
Los Angeles 2
Lurate Caccivio 2
Norwalk 2
Paris 2
Prad am Stilfser Joch 2
Pune 2
Redwood City 2
Udine 2
Vicopisano 2
Abidjan 1
Bagno a Ripoli 1
Bangkok 1
Bremen 1
Brno 1
Castel San Giovanni 1
Denver 1
Impruneta 1
Milan 1
Munich 1
San Marco dei Cavoti 1
Saronno 1
São Paulo 1
Toronto 1
Vancouver 1
Zhengzhou 1
Totale 522
Nome #
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 129
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: The Colon Life nomogram 98
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 92
Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis 89
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 87
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 77
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 76
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 73
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 62
Current status and future perspectives in HER2 positive advanced gastric cancer 61
Totale 844
Categoria #
all - tutte 3.507
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.507


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202021 0 0 0 0 0 0 0 0 0 0 18 3
2020/202193 12 6 7 8 2 5 4 13 5 15 4 12
2021/202247 1 0 7 2 0 1 2 6 0 2 10 16
2022/2023227 9 40 10 8 7 35 26 34 35 0 13 10
2023/2024118 3 11 10 9 9 13 1 29 3 8 13 9
2024/2025338 21 58 27 104 128 0 0 0 0 0 0 0
Totale 844